Castle Biosciences CEO Derek Maetzold disposes of 45,016 common shares worth 1.4 million - CSTL News | RalliesCastle Biosciences CEO Derek Maetzold disposes of 45,016 common shares worth 1.4 million
C
CSTL• CEO reports option exercises and share sales
- Derek J. Maetzold, President and Chief Executive Officer, reported option exercises totaling 22,902 shares at USD 2.39 on Aug. 4-5.
- He reported sales totaling 41,357 shares at weighted-average prices of about USD 30.68 to USD 31.34 over the same period.
- Directly held common stock ended at 21,479 shares following the transactions.
SUN
•
